Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

2(40.0%)

Phase 3

1(20.0%)

5Total

Phase 1(2)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06586866Phase 2Not Yet Recruiting

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

Role: lead

NCT06595186Phase 2Recruiting

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

Role: lead

NCT04366648Phase 1Completed

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor

Role: lead

NCT06581380Phase 3Not Yet Recruiting

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

Role: lead

NCT05158491Phase 1Unknown

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

Role: lead

All 5 trials loaded